Technical analysis of Acadia Pharmaceuticals Inc. (ACAD): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis.
Price Performance
| 1 month | +3.21% |
| 3 months | -28.51% |
| Year-to-date | -22.91% |
| 1 year | -7.96% |
| 3 years | -14.46% |
| 5 years | +2.85% |
| 10 years | -5.07% |
52-Week Range
| 52-week High | $30.96 |
| 52-week Low | $18.39 |
| Avg Volume (90d) | 1.8M |
Technical Indicators
| SMA 50 | $23.74 |
| SMA 200 | $23.68 |
| Beta | 0.83 |
| 30-day Volatility (annualised) | 53.0% |
| Price vs SMA 50 | -13.3% |
| Price vs SMA 200 | -13.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-12 | $26.71 | |
| 2026-01 | $25.13 | -5.9% |
| 2026-02 | $24.56 | -2.3% |
| 2026-03 | $22.26 | -9.4% |
| 2026-04 | $22.45 | +0.9% |
| 2026-05 | $21.66 | -3.5% |
| 2026-06 | $25.30 | +16.8% |
| 2026-07 | $25.87 | +2.3% |
| 2026-08 | $28.91 | +11.8% |
| 2026-09 | $20.15 | -30.3% |
| 2026-10 | $20.59 | +2.2% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-04 | $0.20 | $333M |
| 2026-08-04 | $0.07 | $297M |
| 2026-05-06 | $0.04 | $280M |
| 2026-02-25 | $0.14 | $293M |
| 2025-11-05 | $0.14 | $277M |
| 2025-08-06 | $0.14 | $262M |
| 2025-05-07 | $0.10 | $239M |
Price
| Price | $20.47 (closing price, November 2, 2026) |
| Market Cap | $3.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 9.22 |
| Price / Book | 2.69 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.06 |
| Current Ratio | 3.39 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 7.94 |